retatrutideforsale.xyz
R-30 for $125 withShop

Primary documents · legal

Is retatrutide legal? The complete paper trail, 2023 to 2026

22 FDA warning letters, 11 Lilly lawsuits against sellers, an unresolved appeal over whether retatrutide is a biologic, DOJ cases and seizures in the UK, Australia and Canada, all from primary documents.

By RetatrutideForSale Editorial TeamUpdated 14 min read
On this page
  1. Short answer
  2. Timeline 2023-2026
  3. 22 FDA warning letters
  4. Lilly's lawsuits
  5. Drug or biologic?
  6. DOJ, customs, other countries
  7. What it means for buyers
  8. Open questions and method
  9. FAQ
  10. Sources
  • 22FDA warning letters naming retatrutide since Dec 2024
  • 11Lilly lawsuits against sellers in 2026
  • 0approvals anywhere in the world
  • Q1 2027Lilly's planned U.S. filing

Short answer

Is retatrutide legal? The short answer for 2026

Retatrutide is not approved in any country.

As of 14 October 2026, no regulator has approved it. Lilly says it plans to submit retatrutide for U.S. approval in Q1 2027.[1] Until then, five things hold in the United States:

  • No compounding. FDA says retatrutide cannot be compounded under sections 503A or 503B.[2]
  • “Research use only” is not a shield. When a seller markets it for people, FDA treats it as an unapproved new drug, whatever the label says.[3]
  • Lilly is suing. It filed 11 suits against sellers, clinics and a pharmacy in 2026.[4]
  • DOJ and customs are involved. There are two criminal cases, two civil forfeitures and a customs operation of about 5,000 seized shipments.
  • The classification fight is open. Whether retatrutide is a drug or a biologic is on appeal.

Outside the U.S., the rules differ by country. Regulators in the UK, Australia, Canada, Switzerland and the Philippines have all acted against retatrutide products.

This page reports what public documents say. It is not legal advice; if you need that, ask a lawyer in your jurisdiction.

Master timeline

Retatrutide legal timeline, 2023 to 2026

Here are 25 key dates from primary records.

The full record has more than 50 entries. We kept the ones that changed the legal position or show who is enforcing.

DateEventWho
9 Nov 2023Lilly asks FDA to classify retatrutide as a biologic[5]Lilly
18 Mar 2024FDA designates retatrutide a drug, not a biologic[5]FDA
3 Sep 2024Lilly sues FDA under the Administrative Procedure Act (S.D. Ind.)[6]Lilly
10 Dec 2024First four FDA warning letters naming retatrutide[7]FDA
20 May 2025Pivotal Peptides settles with Lilly and agrees not to sell retatrutide[8]W.D. Wash.
9 Sep 2025Six warning letters over compounded retatrutide sold online[9]FDA
3 Oct 2025Court upholds FDA on “protein”, vacates its “analogous product” finding[5]S.D. Ind.
24 Oct 2025Northampton raid: more than 2,000 retatrutide and tirzepatide pens seized[10]MHRA (UK)
8 Dec 2025Warning letter to API distributor Darmerica[11]FDA
16 Dec 2025Final judgment; “analogous product” question sent back to FDA[12]S.D. Ind.
20 Jan 2026Warning letter to 503B facility GenoGenix for repackaging retatrutide[13]FDA
12 Feb 2026Lilly appeals to the 7th Circuit (No. 26-1301)[6]Lilly
27 Feb 2026Criminal information against the operator of AKT Labs[14]DOJ (M.D. Fla.)
31 Mar 2026Five warning letters to research-use-only sellers[3]FDA
31 Mar 2026About 5,000 peptide shipments from China seized in Cincinnati[15]CBP
1 Apr 2026Utah physician indicted over misbranded peptides incl. retatrutide[16]DOJ (D. Utah)
9 Apr 2026Advisory RA-81874 lists retatrutide among unauthorized peptides[17]Health Canada
28 May 2026Largest UK weight-loss seizure: about 12,000 doses, two arrests[18]MHRA (UK)
23 Jul 2026Lilly says it will submit a BLA for retatrutide in Q1 2027[1]Lilly
12 Aug 2026Six Lilly lawsuits; over 200 referrals and 14,000 listings reported[4]Lilly
24 Aug 2026Five more warning letters to research-use-only sellers[19]FDA
14 Sep 2026“Retatrutide” vial tested: no retatrutide, semaglutide instead[20]TGA (Australia)
24 Sep 20267th Circuit hears argument, orders briefs on its own jurisdiction[21]7th Cir.
6 Oct 2026Advisory 2026-1392 against unregistered retatrutide[22]FDA Philippines
8 Oct 2026Five more Lilly suits; jurisdiction memoranda filed in the appeal[23]Lilly / 7th Cir.
Selected from court dockets, FDA letters and regulator releases. Each row links to its primary source.

FDA enforcement

All 22 FDA warning letters that name retatrutide

FDA has named retatrutide in 22 warning letters.

The first four went out in December 2024.[7] The latest five are dated 24 August 2026.[19] Letters are often posted a week or more after their date.

FDA warning letters naming retatrutide, by batch

Letter date, not posting date. Total: 22.

  • Dec 2024
    RUO peptide sellers    4
  • Sep 2025
    Compounded, sold online    6
  • Dec 2025 to Jan 2026
    API distributor, 503B facility    2
  • Mar 2026
    RUO peptide sellers    5
  • Aug 2026
    RUO peptide sellers    5
Source: our count of FDA warning letters, checked one by one.[7][9][11][13][3][19]

Three legal theories, one per kind of seller

Compounding fails 503A/503B

Used against telehealth sellers in September 2025. Retatrutide has no USP monograph, is not part of an approved drug and is on neither bulks list.[9]

“Research use only” is an unapproved new drug

Used against peptide sellers in 2024 and 2026. FDA looks past the label to the website, and if the evidence shows human use, the product is a drug.[3]

API distribution and repackaging

Darmerica sold retatrutide API to 503A compounders.[11] GenoGenix, a 503B facility, repackaged it.[13]

Code names do not help

Sellers listed it as “GLP-3 RT”, “GLP-3-R”, “GLP-1-R” or “Reta”. FDA named retatrutide anyway. One letter cites a dosing “cheat sheet” going up to 12 mg weekly.[24]

Despite statements on your product labeling marketing your products for “Research Use Only,” ... evidence obtained from your website establishes that your products are intended to be drugs for human use.

U.S. Food and Drug AdministrationWarning letter to Gram Peptides · Mar 31, 2026

Retatrutide and cagrilintide cannot be used in compounding under federal law.

U.S. Food and Drug AdministrationFDA's concerns with unapproved GLP-1 drugs · current Oct 1, 2026
#Letter dateRecipientLocationWhat was soldTheory
110 Dec 2024Prime Vitality dba Prime PeptidesSanta Barbara, CA“Retatrutide”, semaglutide peptidesUnapproved new drug (RUO)
210 Dec 2024Summit Research PeptidesHoover, AL“Reta”, sema, tirz, cagrilintide, mazdutideUnapproved new drug (RUO)
310 Dec 2024SwisschemsNew York, NYRetatrutide, semaglutideUnapproved new drug (RUO)
410 Dec 2024Xcel Research LLCSheridan, WY“RETA”, mazdutide, survodutide, othersUnapproved new drug (RUO)
59 Sep 2025Amazing MedsColorado Springs, COCompounded retatrutide, semaglutide (telehealth)Compounding fails 503A/503B
69 Sep 2025ASN-LABSHonolulu, HICompounded retatrutide, semaglutideCompounding fails 503A/503B
79 Sep 2025EA Works dba Trust LabsSheridan, WYRetatrutide, semaglutide, tirzepatideCompounding fails 503A/503B
89 Sep 2025GenLabMedsU.S.Compounded retatrutide, semaglutide; misleading claimsCompounding fails 503A/503B
99 Sep 2025GLP-1 SolutionBerlin, GermanyCompounded retatrutide, semaglutideCompounding fails 503A/503B
109 Sep 2025MedClub by Dr. JennWest Palm Beach, FLRetatrutide, semaglutideCompounding fails 503A/503B
118 Dec 2025Darmerica LLCDavie, FLRetatrutide API to 503A compoundersAPI distribution (misbranding)
1220 Jan 2026GenoGenix LLC (503B)Boca Raton, FLRepackaged semaglutide, tirzepatide, retatrutideRepackaging; CGMP failures
1331 Mar 2026Gram PeptidesRancho Santa Fe, CA“GLP-1-R peptide” (retatrutide), tirzepatideUnapproved new drug (RUO)
1431 Mar 2026Lovega LLC dba Pink Pony PeptidesWellington, FL“GLP-3 RT”, “GLP-2 TZ”Unapproved new drug (RUO)
1531 Mar 2026Mile High Compounds LLCClifton, CO“GLP-3 RT” plus a dosing “cheat sheet”Unapproved new drug (RUO)
1631 Mar 2026PekCura LabsPensacola, FL“GLP-3-R”Unapproved new drug (RUO)
1731 Mar 2026Prime SciencesScottsdale, AZ“GLP1-R (identified as Retatrutide)”Unapproved new drug (RUO)
1824 Aug 2026NuScience PeptidesCornelius, NC“GLP-3 RT (Retatrutide)”, survodutide, mazdutideUnapproved new drug (RUO)
1924 Aug 2026Peak Performance PeptidesPhoenix, AZ“GLP-3R”Unapproved new drug (RUO)
2024 Aug 2026Peptide Partners LLCSarasota, FL“GLP-3 Reta (Retatrutide)”Unapproved new drug (RUO)
2124 Aug 2026Royal Peptides LLCBoynton Beach, FL“Retatrutide”Unapproved new drug (RUO)
2224 Aug 2026TXP Innovations dba Tex PeptidesDallas, TX“Retatrutide (GLP-3 RT)”Unapproved new drug (RUO)
Each recipient name links to the letter on fda.gov. RUO = sold as “research use only”.

FDA's own summary page lists the same targets: telehealth firms, API distributors, outsourcing facilities and sellers of products falsely labelled “for research purposes.”[2] Import Alert 66-80, last revised 9 October 2026, lets customs detain GLP-1 bulk ingredients from firms not on FDA's green list. It does not name retatrutide; its “Peptide N.E.C.” codes may cover it, but that is our reading.[25]

What happened after the letters?

We found no public FDA injunction or seizure against any of the 22 recipients. A warning letter is a warning, not a court order. Note that TXP Innovations dba “Tex Peptides” (letter 22) is a different company from “Texas Peptides Inc.”, which Lilly is suing.

Private litigation

Lilly's retatrutide lawsuits against sellers

Lilly sued 11 sellers in two waves.

Six suits were filed on 12 August 2026 with a press release.[4] Five more followed on 8 October, with no release.[23] An earlier tirzepatide case, Pivotal Peptides, settled in 2025 with a promise not to sell retatrutide.[8]

Retatrutide cannot legally be sold for human use to anyone, anywhere, for any reason.

Eli Lilly and Company, complaint against Legendary PeptidesE.D. Tex. · Aug 12, 2026
DefendantCourt / numberFiledTypeTheoryStatus (13 Oct 2026)
Pivotal PeptidesW.D. Wash. 2:24-cv-0171921 Oct 2024RUO seller (tirzepatide case)Washington Consumer Protection ActSettled 20 May 2025; agreed not to sell retatrutide
Aesthetic Envy Cosmetic CentersE.D. Cal. 2:26-at-0134712 Aug 2026Med spaLanham Act false advertisingThree docket entries; no service or answer visible
Astra LLC dba Astra PeptidesW.D. Tex. 5:26-cv-0514712 Aug 2026RUO sellerState unfair competitionAmended 31 Aug; voluntary dismissal notice 2 Sep (scope unclear); discovery motion 30 Sep
Legendary PeptidesE.D. Tex. 1:26-cv-0034712 Aug 2026RUO sellerState unfair competitionMotion to dismiss filed 2 Oct 2026
Striker PharmacyS.D. Tex. 4:26-cv-0656312 Aug 2026503A compounding pharmacyState unfair competitionScheduling order 5 Oct; dispositive motions due 10 Aug 2027
Texas Peptides Inc.W.D. Tex. 5:26-cv-0514612 Aug 2026RUO sellerState unfair competitionServed 17 Aug; joint case plan due 2 Nov
Lone Star Peptide Co.S.D. Tex. 4:26-cv-0656212 Aug 2026RUO sellerState unfair competitionNo defense appearance visible (our inference)
Brown (LiveWell Peptides)N.D. Tex. 3:26-cv-035148 Oct 2026RUO sellerState unfair competitionJust filed
Southlake MHYA PLLC (Medrein)N.D. Tex. 4:26-cv-012948 Oct 2026Med spaLanham Act false advertisingReassigned after recusal
MedShape Weight Loss ClinicD. Ariz. 2:26-cv-073618 Oct 2026Clinic chainLanham Act false advertisingRule 12(b) order 13 Oct
Cenexa LabsS.D. Tex. 4:26-cv-088068 Oct 2026RUO sellerState unfair competitionJust filed
American PeptidesW.D. La. 5:26-cv-041468 Oct 2026RUO sellerState unfair competitionJust filed
Docket status from CourtListener as of 13 Oct 2026. Defendant names link to the docket.

Two theories, and no trademark claims

None of the complaints pleads trademark infringement.

  • Three clinics and med spas face Lanham Act section 43(a)(1)(B) false-advertising claims.
  • Seven RUO sellers and one pharmacy face eight unfair-competition counts each: statutes in Alaska, Colorado, Connecticut, North Carolina, South Carolina, Tennessee and Washington, plus Texas common law. The underlying violations are state food-and-drug laws.[26]

Lilly asks for injunctions against selling anything “containing or purporting to contain retatrutide”, plus damages, disgorgement and fees.

What defendants say back

Legendary Peptides moved to dismiss on 2 October. It argues Lilly lacks standing, that its theory rests on Reddit posts, and that Texas allows no common-law claim built on the state drug act.[27]

Lilly seeks damages for lost sales due to a product it does not and cannot lawfully sell.

Legendary Peptides, motion to dismissE.D. Tex. · Oct 2, 2026

Striker Pharmacy has previewed a different defense. It says FDCA section 337(a) leaves enforcement to the federal government, calls disgorgement a windfall, and wants to depose FDA officials about Lilly's own pre-approval access program. Dispositive motions there are not due until 10 August 2027.[28]

A court mix-up in Lilly's release

Lilly's 12 August release places the Aesthetic Envy case in the Northern District of California. The docket is in the Eastern District, number 2:26-at-01347. An “at” number means no judge had been assigned at filing.[29]

What is being sold on the black market is not a medicine

David Hyman, chief medical officer, Eli LillyLilly press release · Aug 12, 2026

Lilly v. Kennedy

Is retatrutide a drug or a biologic?

The fight turns on one amino acid.

A “protein”, and so a biologic, needs more than 40 alpha amino acids. Retatrutide has 39 alpha amino acids in its backbone plus a side chain. FDA counted at most 40 alpha amino acids plus one non-alpha, and on 18 March 2024 called it a drug.[5] Lilly counts 41 in total.

The district court split the difference

Judge Tanya Walton Pratt ruled for FDA on the protein question. She ruled for Lilly on whether retatrutide is an “analogous product” and sent that issue back to FDA.[5][12]

the regulation unambiguously requires that proteins contain at least forty-one alpha amino acids.

U.S. District Court, S.D. IndianaAmended order · Oct 3, 2025

FDA's “bright line” approach flouts the statutory text and sidesteps congressional intent.

U.S. District Court, S.D. IndianaAmended order · Oct 3, 2025

The appeal is argued but undecided

Lilly appealed anyway.[30] It argues that FDA's 60-day deadline had passed, so the court should have made Lilly's classification final instead of remanding. The government says only alpha amino acids count and that the remand cannot be appealed.[31]

A panel of Chief Judge Brennan and Judges Easterbrook and Kirsch heard argument on 24 September 2026. It ordered extra memoranda on whether it has jurisdiction at all.[21] Both sides filed them on 8 October. There was no ruling as of 13 October.[30]

Why the label matters

IssueIf a drugIf a biologic
Market exclusivity5 years (new chemical entity)12 years before a biosimilar
Medicare price negotiationExempt for 7 yearsExempt for 11 years
Compounding after approval503A/503B rules can applyGenerally outside 503A/503B
Exclusivity per 42 U.S.C. 262(k)(7) and 21 U.S.C. 355(c)(3)(E); Medicare figures as stated in the OFA amicus brief.

The government's brief concedes that biologics get “substantially longer exclusivity.”[31] The trade group for 503B outsourcing facilities filed in support of FDA.[32]

If retatrutide is a biologic, Lilly will receive an enormous windfall at the expense of patients.

Outsourcing Facilities Association, amicus brief7th Cir. · May 19, 2026

Lilly is entitled to finality on the decision of whether retatrutide is a biological product

Eli Lilly and Company, reply brief7th Cir. · Jun 5, 2026

In that June brief, Lilly said almost six months had passed with no new FDA decision on remand.[33] We found none since. Meanwhile Lilly's July release says it will file a Biologics License Application.[1] How a BLA proceeds while FDA's drug designation stands is not explained in any document we found.

Criminal, customs and international

Retatrutide cases beyond FDA letters

Retatrutide enforcement now includes criminal charges.

U.S. v. Taylor (M.D. Fla.)

AKT Labs sold “Retatrutide 5mg” as a “research chemical.” Its operator was charged in February 2026; a guilty-plea hearing entry is dated 26 August.[14] Counts and sentencing are not confirmed.

U.S. v. Watkins (D. Utah)

A Utah osteopathic physician faces 8 counts for receiving misbranded peptides, including retatrutide, from China and selling them to more than 200 patients. Trial is set for 18 December 2026.[16]

W.D. Missouri forfeitures

Two civil forfeiture complaints filed in June 2026 target property tied to Blome Research, an online seller of retatrutide, semaglutide and tirzepatide.[34]

CBP Cincinnati

Between December 2025 and March 2026, officers seized about 5,000 mis-manifested peptide shipments from China.[15]

On 18 September 2026, a 20-state attorney general coalition wrote to the Secretary of State about Chinese GLP-1 ingredients, naming retatrutide.[35] We found no state lawsuit specific to retatrutide.

Outside the United States

  • UK. The MHRA has raided three sites: Northampton (October 2025, over 2,000 pens),[10] Lincolnshire and Nottinghamshire (February 2026, about 2,000 doses)[36] and Northamptonshire (May 2026, about 12,000 doses, two arrests).[18]
  • Australia. The TGA and NSW Police seized more than A$120,000 of peptides, including retatrutide, in August 2026.[37] In September the TGA tested a “retatrutide” vial linked to a torn oesophagus.[20]
  • Canada. Health Canada's April 2026 advisory lists retatrutide among unauthorized peptides.[17] Lilly Canada issued its own safety notice in August.[38]
  • Switzerland. Swissmedic warned in August 2025 about a black-market “retatrutide injection kit.”[39]
  • Philippines. FDA Philippines warned against unregistered 30 mg retatrutide on 6 October 2026.[22]

the product contained undeclared semaglutide and no retatrutide.

Therapeutic Goods Administration (Australia)Safety alert · Sep 14, 2026

We found no EMA or German BfArM warning. For athletes, retatrutide is not named on WADA's 2026 Prohibited List. Section S0 bans any substance without government approval for human use, “e.g. drugs under pre-clinical or clinical development.”[40] Whether that catches retatrutide is an open question WADA has not answered.

Practical reading

What the retatrutide legal record means for buyers

The targets so far are sellers, not buyers.

The pattern is consistent. FDA letters and Lilly suits go after sellers that market for human use: they give dosing, make treatment claims, or run clinics and telehealth services. For the research-use-only sellers among the 22 letter recipients, the label did not help.[2][3]

The second risk is authenticity. The TGA's vial held semaglutide at about 8 times the approved strength and no retatrutide.[20] CBS reports two deaths submitted to FDA's adverse event database involving products sold as retatrutide. Those are FOIA'd reports that FDA has not verified.[41]

People comparing vendor prices and certificates for retatrutide for sale should keep both points in mind. A low price or a clean certificate does not change the legal status above. Our COA and lab testing analysis shows how often vendor certificates and independent tests disagree.

Outside trials, the only sanctioned access is Lilly's expanded-access program. It is limited to people with a BMI of 35 or more, two or more serious complications, no response to approved therapy and no trial option.[42] For what clinicians think of the drug itself, see our retatrutide expert opinions roundup.

Open questions and method

What is still unknown about retatrutide's legal status

Several big questions remain unresolved.

  • Will the 7th Circuit rule on the merits, or dismiss for lack of appellate jurisdiction?
  • Has FDA issued a new “analogous product” decision on remand? We found none.
  • How will Lilly file a BLA while the drug designation stands, and has FDA accepted that pathway?
  • What exactly did the 2 September voluntary dismissal in the Astra case dismiss? The filing is not public on RECAP.
  • Was the Aesthetic Envy case served, refiled under a full number, or dropped?
  • Which counts did the AKT Labs operator plead to, and when is sentencing?
  • Is any retatrutide seller on Import Alert 66-41 or the 66-80 red list?
  • What do the two reported deaths show? Only CBS has described them so far.
  • Does WADA's S0 rule cover retatrutide?

How we did this

We searched FDA's full-text warning-letter index for “retatrutid”, “GLP-3”, “GLP3”, “LY3437943” and “triple agonist.” That returned 23 letters; one (AstraZeneca, 2023) did not mention retatrutide, leaving 22. We read each letter in full. Court records come from CourtListener's RECAP archive and docket lists, checked through 13 October 2026.

The limits are real. RECAP holds only documents someone has bought, so some filings are missing. FDA's 2024 designation letter is sealed. We left out FDA's March 2025 letter to state medical boards and a Connecticut attorney general settlement because we could not open the primary pages. We did not transcribe the appeal audio.

FAQ

Frequently asked questions

Is it legal to buy retatrutide in the US?

No retatrutide product is approved, so there is no lawful prescription product to buy. FDA treats retatrutide sold as 'research use only' but marketed for people as an unapproved new drug, and Lilly says it cannot legally be sold for human use. The public actions we found target sellers, clinics, a pharmacy, an API distributor and a physician who resold to patients, not individual end users. That is a description of the record, not legal advice.

Can a doctor prescribe retatrutide or a pharmacy compound it?

There is no approved retatrutide to prescribe. FDA says retatrutide cannot be used in compounding under federal law because it has no USP monograph, is not part of an approved drug and is not on the 503A or 503B bulks lists. Outside clinical trials, the only sanctioned route is Lilly's expanded-access program (NCT07629401), which is limited to people with a BMI of 35 or more, at least two serious complications and no response to approved therapy.

Is retatrutide legal in the UK, Australia or Canada?

It is not approved in any of them. The MHRA has raided three UK production sites since October 2025, the TGA has seized peptides including retatrutide and tested a counterfeit vial, and Health Canada listed retatrutide among unauthorized injectable peptides in April 2026. Each country has its own rules on possession and import, so check the local regulator.

Is retatrutide banned by WADA?

Retatrutide is not named on WADA's 2026 Prohibited List, and the monitoring program covers only semaglutide and tirzepatide. However, section S0 bans any substance with no current approval by a government health authority, including drugs in clinical development. Whether S0 catches retatrutide has not been stated by WADA, so athletes should ask WADA or their national anti-doping agency.

Why is Lilly suing sellers of a drug it does not sell yet?

Lilly argues that unapproved retatrutide sales break state food-and-drug laws, which it pleads as unfair competition, and that clinics advertising it make false claims under the Lanham Act. Defendants answer that Lilly cannot be harmed by sales of a product it does not and cannot lawfully sell. No court has ruled on that standing argument yet.

Will the 7th Circuit appeal decide whether retatrutide is legal?

No. Lilly v. Kennedy asks whether retatrutide is a drug or a biologic, which affects exclusivity, Medicare negotiation timing and compounding rules after approval. It does not change the current position that retatrutide is unapproved. The court heard argument on Sep 24, 2026 and had not ruled as of Oct 14.

Our pickAscension R-30 retatrutide 30 mg vial

Comparing vendors? Start with the price table.

Our retatrutide for sale guide compares price per mg across 10 vendors and shows the batch certificates behind our pick: Ascension R-30, $125 with code PEPTIDEDECK.

Get 50% off R-30

Affiliate link. We earn a commission at no extra cost to you.

References

Sources

  1. Eli Lilly and Company. Lilly's triple agonist retatrutide successful in two additional phase 3 obesity trials. PR Newswire, Jul 23, 2026. Link
  2. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Page current as of Oct 1, 2026. Link
  3. FDA CDER. Warning letter to Gram Peptides, Mar 31, 2026. Link
  4. Eli Lilly and Company. Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market. PR Newswire, Aug 12, 2026. Link
  5. U.S. District Court, S.D. Indiana. Eli Lilly v. Kennedy, 1:24-cv-01503, amended order on cross-motions for summary judgment (Dkt 48), Oct 3, 2025. Link
  6. CourtListener. Eli Lilly and Company v. Kennedy, S.D. Ind. 1:24-cv-01503, docket. Link
  7. FDA. FDA Roundup: December 17, 2024. Link
  8. U.S. District Court, W.D. Washington. Eli Lilly v. Pivotal Peptides, 2:24-cv-01719, stipulated settlement order (Dkt 39), May 20, 2025. Link
  9. FDA CDER. Warning letter to Amazing Meds, Sep 9, 2025. Link
  10. MHRA. MHRA smashes major illicit weight loss medicine production facility in record seizure. GOV.UK, Oct 2025. Link
  11. FDA CDER. Warning letter to Darmerica LLC, Dec 8, 2025. Link
  12. U.S. District Court, S.D. Indiana. Eli Lilly v. Kennedy, final judgment (Dkt 54), Dec 16, 2025. Link
  13. FDA CDER. Warning letter to GenoGenix LLC, Jan 20, 2026. Link
  14. CourtListener. United States v. Taylor, M.D. Fla. 3:26-cr-28, docket. Link
  15. U.S. Customs and Border Protection. Cincinnati CBP foils scheme to smuggle over 5,000 unapproved peptides into U.S. Mar 31, 2026. Link
  16. U.S. Attorney's Office, District of Utah. Utah licensed osteopathic physician indicted for allegedly receiving misbranded drugs from China. Apr 2026. Link
  17. Health Canada. Think twice before injecting peptides bought online (advisory RA-81874). Apr 9, 2026. Link
  18. MHRA. Two arrested during the MHRA's largest ever seizure of unlicensed weight loss medicines. GOV.UK, May 2026. Link
  19. FDA CDER. Warning letter to TXP Innovations LLC dba Tex Peptides, Aug 24, 2026. Link
  20. Therapeutic Goods Administration. TGA tests counterfeit retatrutide product following serious adverse event report. Sep 14, 2026. Link
  21. U.S. Court of Appeals for the Seventh Circuit. Oral argument audio, No. 26-1301, Sep 24, 2026. Link
  22. Food and Drug Administration Philippines. FDA Advisory No. 2026-1392 against the unregistered drug product Retatrutide. Oct 6, 2026. Link
  23. CourtListener. Eli Lilly v. Brown (LiveWell Peptides), N.D. Tex. 3:26-cv-03514, docket. Link
  24. FDA CDER. Warning letter to Mile High Compounds LLC, Mar 31, 2026. Link
  25. FDA. Import Alert 66-80: Detention without physical examination of GLP-1 receptor agonist bulk drug substances. Revised Oct 9, 2026. Link
  26. CourtListener. Eli Lilly v. Legendary Peptides, E.D. Tex. 1:26-cv-00347, docket and complaint. Link
  27. Legendary Peptides, LLC. Motion to dismiss (Dkt 12), E.D. Tex. 1:26-cv-00347, Oct 2, 2026. Link
  28. U.S. District Court, S.D. Texas. Eli Lilly v. Striker Pharmacy, 4:26-cv-06563, scheduling order (Dkt 28), Oct 5, 2026. Link
  29. CourtListener. Eli Lilly v. Aesthetic Envy Cosmetic Centers, E.D. Cal. 2:26-at-01347, docket. Link
  30. CourtListener. Eli Lilly v. Kennedy, 7th Cir. No. 26-1301, docket. Link
  31. U.S. Department of Justice. Brief for the federal appellees (Dkt 23), 7th Cir. No. 26-1301, May 15, 2026. Link
  32. Outsourcing Facilities Association. Amicus brief supporting appellees (Dkt 27), 7th Cir. No. 26-1301, May 19, 2026. Link
  33. Eli Lilly and Company. Reply brief (Dkt 31), 7th Cir. No. 26-1301, Jun 5, 2026. Link
  34. CourtListener. United States v. property linked to Blome Research, W.D. Mo. civil forfeiture, docket. Link
  35. Iowa Attorney General. Attorney General Brenna Bird urges federal government to crack down on dangerous counterfeit Chinese drugs (20-state letter). Sep 18, 2026. Link
  36. MHRA. MHRA disrupts second manufacturing facility suspected to be involved in the manufacture of illegal weight loss medicines. GOV.UK, Feb 2026. Link
  37. Therapeutic Goods Administration. TGA flexes its muscle against illegal peptides and steroids. Aug 17, 2026. Link
  38. Eli Lilly Canada. Retatrutide: Canadian public safety notice. Aug 13, 2026. Link
  39. Swissmedic. Swissmedic warns about GLP-1 products. Aug 26, 2025. Link
  40. World Anti-Doping Agency. Prohibited List (2026), section S0 Non-approved substances. Link
  41. CBS News. Deaths reported to FDA involving bootleg 'reta' weight-loss drug. Oct 2026 (secondary; reports not verified by FDA). Link
  42. ClinicalTrials.gov. NCT07629401: expanded access to retatrutide. Last updated Aug 3, 2026. Link

Keep reading

More retatrutide research

Disclaimer. For information only; not medical, legal or purchasing advice. Retatrutide is an investigational compound that has not been approved by the FDA or any other regulator. Products referenced on this site are sold for laboratory research and are not intended for human use. We earn a commission on purchases from Ascension Peptides made through our links.

$125R-30 · code PEPTIDEDECK
Get 50% off